US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% NVDA $233.95 ▲+0.00% SNDK $1,719.99 ▲+0.00% SDEV $7.48 ▲+0.00% SPCX $158.96 ▲+0.00% AMD $633.91 ▲+0.00% TSLA $370.59 ▲+0.00%
FinancialContent

Articles published by Ovid Therapeutics Inc.

< Previous 1 2 Next >
News headline image
Ovid Therapeutics to Participate in Upcoming Investor Conferences
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics to Participate in Upcoming Investor Conferences
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics Announces Pricing of $60 Million Private Placement
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics to Participate in Upcoming Investor Conferences
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics to Present Multiple Posters Supporting Its Pipeline Programs Targeting Neuronal Hyperexcitability at the American Epilepsy Society 2024 Annual Meeting
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics to Host Investor Event
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with Vigabatrin
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics to Present at Upcoming September Investor Conferences
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
< Previous 1 2 Next >